Stephen Kraus is partner at Bessemer Venture Partners and leads up the firm’s healthcare investing activities.
He currently sits on the boards of Health Essentials, DocuTAP, Ovascience (NASDAQ: OVAS), Flex Pharma Allena Pharmaceuticals and Alcresta and is actively involved in BVP's investments in Proteon. Steve has been actively involved in Bessemer’s investments in Liazon, acquired by Towers Watson; Sirtris Pharmaceuticals (NASDAQ: SIRT, acquired by GlaxoSmithKline); Affymax (NASDAQ:AFFY); Aveo (NASDAQ: AVEO); Alnara, acquired by Eli Lilly; Transave (NASDAQ: INSM); Stromedix, acquired by Biogen Idec, Verastem (NASDAQ: VSTM), Acceleron (NASDAQ: XLRN) and Restore Medical (NASDAQ: REST), acquired by Medtronic. Steve has been recognized by Forbes Magazine as one of the top healthcare investors in the industry.
Prior to joining Bessemer, Steve worked for a growth-stage, private-equity firm and as a management consultant at Bain & Company. He has also worked on several different political campaigns throughout his career.
Steve graduated summa cum laude with a B.A. from Yale University and earned his MBA from Harvard, where he was a Baker Scholar. He serves as Chair of the board of the New England Venture Capital Association (NEVCA) and the Achievement Network.
Steve regularly blogs with BVP's Ambar Bhattacharyya at (two healthcare investors' musings on work and life).